Effective February 1, 2026, Texas Medicaid will expand coverage for revakinagene-taroretcel-lwey (Encelto) procedure code J3403 to include additional provider types: free-standing, independent, and hospital ambulatory surgical centers in outpatient hospital settings. This expands who can bill for this specialized drug treatment.
Get alerts when payers change rules like this one
We check Texas Medicaid and other payers every day and email you when a change matches your specialty and state.
01Before February 1, 2026: Billing team must verify if practice operates free-standing, independent, or hospital ambulatory surgical centers that provide outpatient services.
02If applicable, update billing system to enable J3403 claims submission for revakinagene-taroretcel-lwey (Encelto) treatments.
03Contact TMHP at 800-925-9126 for specific billing requirements and ensure proper provider enrollment for this expanded coverage.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.